Allogene Therapeutics Inc (NAS:ALLO)
$ 2.99 -0.01 (-0.33%) Market Cap: 625.25 Mil Enterprise Value: 269.70 Mil PE Ratio: 0 PB Ratio: 1.22 GF Score: 34/100

Q3 2021 Allogene Therapeutics Inc Earnings Call Transcript

Nov 04, 2021 / 09:00PM GMT
Release Date Price: $19.43 (-3.62%)
Operator

Hello. Thank you for standing by, and welcome to Allogene Therapeutics' Third Quarter 2021 Conference Call. (Operator Instructions) Please be aware that today's conference is being recorded. I would now like to hand the conference over to Christine Cassiano, Chief Communications Officer. Ms. Cassiano, you may begin.

Christine Cassiano
Allogene Therapeutics, Inc. - Chief Communications Officer

Thank you, operator, and welcome to all who joined the call. After the market closed today, Allogene issued a press release that provides a corporate update and financial results for Q3 2021. This press release and today's webcast are both available on our website. Joining me on the call today are Dr. David Chang, President and Chief Executive Officer; Dr. Rafael Amado, Executive Vice President of Research and Development and Chief Medical Officer; and Dr. Eric Schmidt, Chief Financial Officer.

During today's call, we will be making certain forward-looking statements. These may include statements regarding the timing and ability to advance our clinical trials and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot